Mostrar o rexistro simple do ítem
Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study
dc.contributor.author | Pischedda, Sara | |
dc.contributor.author | Rivero Calle, Irene | |
dc.contributor.author | Gómez Carballa, Alberto | |
dc.contributor.author | Cebey-López, M. | |
dc.contributor.author | Barral-Arca, R. | |
dc.contributor.author | Gomez Rial, Jose | |
dc.contributor.author | Pardo Seco, Jacobo José | |
dc.contributor.author | Currás Tuala, María José | |
dc.contributor.author | Viz Lasheras, Sandra | |
dc.contributor.author | Bello, X. | |
dc.contributor.author | Crujeiras Martínez, Ana Belén | |
dc.contributor.author | Díaz Lagares, Ángel | |
dc.contributor.author | González-López, M.T. | |
dc.contributor.author | Martinón Torres, Federico | |
dc.contributor.author | Salas Ellacuriaga, Antonio | |
dc.date.accessioned | 2025-08-26T08:47:45Z | |
dc.date.available | 2025-08-26T08:47:45Z | |
dc.date.issued | 2022 | |
dc.identifier.citation | Pischedda S, Rivero-Calle I, Gómez-Carballa A, Cebey-López M, Barral-Arca R, Gómez-Rial J, et al. Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study. Frontiers in Immunology. 2022;13. | |
dc.identifier.issn | 1664-3224 | |
dc.identifier.other | https://portalcientifico.sergas.gal/documentos/62e5c376e5f0e01a6a1d0b72 | * |
dc.identifier.uri | http://hdl.handle.net/20.500.11940/20594 | |
dc.description.abstract | Background: Respiratory syncytial virus (RSV) infection has been associated with the subsequent development of recurrent wheezing and asthma, although the mechanisms involved are still unknown. We investigate the role of epigenetics in the respiratory morbidity after infection by comparing methylation patterns from children who develop recurrent wheezing (RW-RSV), subsequent asthma (AS-RVS), and those experiencing complete recovery (CR-RSV). Methods: Prospective, observational study of infants aged < 2 years with RSV respiratory infection admitted to hospital and followed-up after discharge for at least three years. According to their clinical course, patients were categorized into subgroups: RW-RSV (n = 36), AS-RSV (n = 9), and CR-RSV (n = 32). The DNA genome-wide methylation pattern was analyzed in whole blood samples, collected during the acute phase of the infection, using the Illumina Infinium Methylation EPIC BeadChip (850K CpG sites). Differences in methylation were determined through a linear regression model adjusted for age, gender and cell composition. Results: Patients who developed respiratory sequelae showed a statistically significant higher proportion of NK and CD8T cells (inferred through a deconvolution approach) than those with complete recovery. We identified 5,097 significant differentially methylated positions (DMPs) when comparing RW-RSV and AS-RVS together against CR-RSV. Methylation profiles affect several genes involved in airway inflammation processes. The most significant DMPs were found to be hypomethylated in cases and therefore generally leading to overexpression of affected genes. The lead CpG position (cg24509398) falls at the gene body of EYA3 (P-value = 2.77×10-10), a tyrosine phosphatase connected with pulmonary vascular remodeling, a key process in the asthma pathology. Logistic regression analysis resulted in a diagnostic epigenetic signature of 3-DMPs (involving genes ZNF2698, LOC102723354 and RPL15/NKIRAS1) that allows to efficiently differentiate sequelae cases from CR-RSV patients (AUC = 1.00). Enrichment pathway analysis reveals the role of the cell cycle checkpoint (FDR P-value = 4.71×10-2), DNA damage (FDP-value = 2.53×10-2), and DNA integrity checkpoint (FDR P-value = 2.56×10-2) in differentiating sequelae from CR-RSV patients. Conclusions: Epigenetic mechanisms might play a fundamental role in the long-term sequelae after RSV infection, contributing to explain the different phenotypes observed. | en |
dc.description.sponsorship | This study received support from Instituto de Salud Carlos III ( ISCIII): GePEM (PI16/01478/Cofinanciado FEDER; AS), DIAVIR ( DTS19/ 00049/Cofinanciado FEDER, AS), ResviOmics (PI19/01039/ Cofinanciado FEDER, AS), Agencia Gallega de Innovacio ' n (GAIN): Grupos con Potencial de Crecimiento (IN607B 2020/ 08, AS); Agencia Gallega para la Gestio ' n del Conocimiento en Salud (ACIS): BI-BACVIR (PRIS3, AS), and CovidPhy (SA 304 C, AS); ReSVinext (PI16/ 01569/ Cofinanciado FEDER, FM-T), Enterogen ( PI19/01090/ Cofinanciado FEDER, FM- T) and consorcio Centro de Investigacio ' n Biome ' dica en Red de Enfermedades Respiratorias (CB21/06/00103; FM-T; GEN-COVID (IN845D 2020/23, FM- T) and Grupos de Referencia Competitiva ( IIN607A2021/05, FM- T). AD-L is funded by a contract Juan Rode ' s from ISCIII (JR17/00016). ABC is a Miguel Servet researcher (ISCIII; CP17/0008). The funders were not involved in the study design, collection, analysis, interpretation of data, the writing of this article or the decision to submit it for publication. | en |
dc.language.iso | eng | |
dc.rights | Atribución 4.0 Internacional | * |
dc.rights.uri | http://creativecommons.org/licenses/by/4.0/ | |
dc.title | Role and Diagnostic Performance of Host Epigenome in Respiratory Morbidity after RSV Infection: The EPIRESVi Study | * |
dc.type | Article | en |
dc.authorsophos | Pischedda, A. S. | |
dc.authorsophos | Rivero-Calle, I. | |
dc.authorsophos | Gómez-Carballa, A. | |
dc.authorsophos | Cebey-López, M. | |
dc.authorsophos | Barral-Arca, R. | |
dc.authorsophos | Gómez-Rial, J. | |
dc.authorsophos | Pardo-Seco, J. | |
dc.authorsophos | Curras-Tuala, M. J. | |
dc.authorsophos | Viz-Lasheras, S. | |
dc.authorsophos | Bello, X. | |
dc.authorsophos | Crujeiras, A. B. | |
dc.authorsophos | Diaz-Lagares, A. | |
dc.authorsophos | González-López, M. T. | |
dc.authorsophos | Martinón-Torres, F. | |
dc.authorsophos | Salas | |
dc.identifier.doi | 10.3389/fimmu.2022.875691 | |
dc.identifier.sophos | 62e5c376e5f0e01a6a1d0b72 | |
dc.journal.title | Frontiers in Immunology | * |
dc.relation.projectID | Instituto de Salud Carlos III | |
dc.relation.publisherversion | https://www.frontiersin.org/articles/10.3389/fimmu.2022.875691/pdf;https://www.frontiersin.org/journals/immunology/articles/10.3389/fimmu.2022.875691/pdf | es |
dc.rights.accessRights | openAccess | |
dc.subject.keyword | AS Santiago | es |
dc.subject.keyword | IDIS | es |
dc.subject.keyword | CHUS | es |
dc.typefides | Artículo Científico (incluye Original, Original breve, Revisión Sistemática y Meta-análisis) | es |
dc.typesophos | Artículo Original | es |
dc.volume.number | 13 |
Ficheiros no ítem
Este ítem aparece na(s) seguinte(s) colección(s)
